Skip to Main Content
Skip Nav Destination

Diabetes Core Update Podcasts

Diabetes Core Update is a monthly audio podcast devoted to presenting and discussing the latest clinically relevant articles from ADA’s four scholarly journals— DiabetesDiabetes CareClinical Diabetes, and Diabetes Spectrum—as well as notable articles from other journals related to diabetes research and care. Each episode is approximately 30 minutes long and includes discussion of 4–6 recently published articles and interviews with authors. Intended for the busy health care professional Diabetes Core Update examines how the latest research and information published in ADA journals and beyond are relevant to clinical practice and can be applied in a treatment setting.

For more information about each of ADA’s science and medical journals, please visit

Presented by:
Neil Skolnik, M.D. , Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

Play Episode

Diabetes Core Update July 2024



Total Time: 37:54 | File Size: 52 MB


Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists. Emanuel et al. N Engl J Med 2024;390(20):1839-1842.

Medical Assistant Health Coaching for Type 2 Diabetes in Primary Care: Results From a Pragmatic Cluster Randomized Controlled Trial. Fortmann et al. Diabetes Care 2024;47(7):1171-1180.

Glycemic Control, Cognitive Aging, and Impairment Among Diverse Hispanic/Latino Individuals: Study of Latinos- Investigation of Neurocognitive Aging (Hispanic Community Health Study/Study of Latinos). González et al. Diabetes Care 2024;47(7):1152-1161.

Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. Loomb et al. N Engl J Med 2024;Jun 8. doi: 10.1056/NEJMoa2401943. Epub ahead of print.

Is Weight Loss-Induced Muscle Mass Loss Clinically Relevant? Conte et al. JAMA 2024;Jun 3. doi: 10.1001/jama.2024.6586. Epub ahead of print.

Play Episode

Diabetes Core Update June 2024



Total Time: 54:00 | File Size: 75 MB


Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. Kosiborod et al. N Engl J Med 2024;390(15):1394–1407.

Habitual Short Sleep Duration, Diet, and Development of Type 2 Diabetes in Adults. Nôga et al. JAMA Netw Open 2024;7(3):e241147.

Effects of Tirzepatide Versus Basal Insulins in People With Type 2 Diabetes and Different Baseline Glycemic Patterns: Post Hoc Analyses of the SURPASS-3 and SURPASS-4 Trials. Giorgino et al. Diabetes Care 2024;47(6):1020–1027.

Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program. Zeitler et al. Diabetes Care 2024;47(6):1056–1064.

Cardiovascular and mortality benefits of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists as third-step glucose-lowering medicine in patients with type 2 diabetes: a retrospective cohort analysis. McCormick et al. BMJ Open Diabetes Res Care 2024;12(3):e003792.

Association of Continued Use of SGLT2 Inhibitors From the Ambulatory to Inpatient Setting With Hospital Outcomes in Patients With Diabetes: A Nationwide Cohort Study. Singh et al. Diabetes Care 2024;47(6):933–940.

Play Episode

Diabetes Core Update May 2024



Total Time: 25:33 | File Size: 35 MB


Loneliness and the risk of type 2 diabetes. Rosenkilde et al. BMJ Open Diabetes Res Care 2024;12(2):e003934.

Microplastics and Nanoplastics in Atheromas and Cardiovascular Events. Marfella et al. N Engl J Med 2024;390(10):900–910.

Efficacy and safety of tirzepatide in people with type 2 diabetes by baseline body mass index: An exploratory subgroup analysis of SURPASS-AP-Combo. Ma et al. Obes Metab 2024;26(4):1454–1463.

Comparing Continuous Glucose Monitoring and Blood Glucose Monitoring in Adults With Inadequately Controlled, Insulin-Treated Type 2 Diabetes (Steno2tech Study): A 12-Month, Single-Center, Randomized Controlled Trial. Lind et al. Diabetes Care 2024;47(5):881–889.

Influence of a diet and/or exercise intervention on long-term mortality and vascular complications in people with impaired glucose tolerance: Da Qing Diabetes Prevention Outcome study. Yu et al. Diabetes Obes Metab 2024;26(4):1188-1196.

Timing of Moderate to Vigorous Physical Activity, Mortality, Cardiovascular Disease, and Microvascular Disease in Adults With Obesity. Sabag et al. Diabetes Care 2024;47(5):890–897.

Play Episode

Diabetes Core Update April 2024



Total Time: 53:52 | File Size: 74 MB


A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. Harrison et al. N Engl J Med 2024;390(6):497–509.

Long-Term Outcomes of Medical Management vs Bariatric Surgery in Type 2 Diabetes. Courcoulas et al. JAMA 2024;331(8):654–664.

Improved Glycemic Outcomes With Diabetes Technology Use Independent of Socioeconomic Status in Youth With Type 1 Diabetes. Lomax et al. Diabetes Care 2024;47(4):707–711.

Cardiovascular and Kidney Risks in Individuals With Type 2 Diabetes: Contemporary Understanding With Greater Emphasis on Excess Adiposity. Sattar et al. Diabetes Care 2024;47(4):531–543.

Epidemiology and Prognostic Implications of Coronary Artery Calcium in Asymptomatic Individuals With Prediabetes: A Multicohort Study. Al Rifai et al. Diabetes Care 2024;47(4):698–706.

Play Episode

Diabetes Core Update March 2024



Total Time: 24:05 | File Size: 33 MB


Leisure-Time Physical Activity May Attenuate the Impact of Diabetes on Cognitive Decline in Middle-Aged and Older Adults: Findings From the ELSA-Brasil Study. Feter et al. Diabetes Care 2024;47(3):427–434.

Outcomes of SGLT-2i and GLP-1RA Therapy Among Patients With Type 2 Diabetes and Varying NAFLD Status. Bea et al. JAMA Netw Open 2024;6(12):e2349856.

Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes. Paik et al. JAMA Intern Med 2024; Epub ahead of print Jan 29:e237660.

Association of Body Weight Time in Target Range With the Risk of Kidney Outcomes in Patients With Overweight/Obesity and Type 2 Diabetes Mellitus. Zu et al. Diabetes Care 2024;47(3):371–378.

Modifiable Lifestyle Factors, Genetic Risk, and Incident Peripheral Artery Disease Among Individuals With Type 2 Diabetes: A Prospective Study. Zhu et al. Diabetes Care 2024;2024;47(3):435–443.

Play Episode

Diabetes Core Update February 2024



Total Time: 33:28 | File Size: 46 MB


Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. Aronne et al. JAMA 2024;331(1):38–48.

Occurrence of Gastrointestinal Adverse Events Upon GLP-1 Receptor Agonist Initiation With Concomitant Metformin Use: A Post Hoc Analysis of LEADER, STEP 2, SUSTAIN-6, and PIONEER 6. Klein et al. Diabetes Care;2024;47(2):280–284.

Diagnostic yield of a proactive strategy for early detection of cardiovascular disease versus usual care in adults with type 2 diabetes or chronic obstructive pulmonary disease in primary care in the Netherlands (RED-CVD): a multicentre, pragmatic, cluster-randomised, controlled trial. Groenewegen et al. Lancet Public Health 2023; Epub ahead of print December 19, 2023.

Low-Dose Antithymocyte Globulin: A Pragmatic Approach to Treating Stage 2 Type 1 Diabetes. Foster et al. Diabetes Care 2024;47(2):285–289.

Assessment of Glycemic Control by Continuous Glucose Monitoring, Hemoglobin A1c, Fructosamine, and Glycated Albumin in Patients With End-Stage Kidney Disease and Burnt-Out Diabetes. Kaminski et al. Diabetes Care 2024;47(2):267–271.

Play Episode

Diabetes Core Update January 2024



Total Time: 35:10 | File Size: 49 MB


Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. Lincoff et al. N Engl J Med 2023;389(24):2221–2232.

Economic Costs of Diabetes in the U.S. in 2022. Parker et al. Diabetes Care 2023;47(1):26–43.

Intensive Lifestyle Intervention for Remission of Early Type 2 Diabetes in Primary Care in Australia: DiRECT-Aus. Hocking et al. Diabetes Care 2023;47(1):66–70.

Efficacy and Safety of Continuous Glucose Monitoring and Intermittently Scanned Continuous Glucose Monitoring in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis of Interventional Evidence. Seidu et al. Diabetes Care 2023;47(1):169–179.

Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Ndumele et al. Circulation 2023;148(20):1606–1635.

Play Episode

Diabetes Core Update December 2023



Total Time: 38:28 | File Size: 53 MB


Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial. Rosenstock et al. JAMA 2023;330(17):1631–1640.

Impact of Guideline-Directed Statin Intervention for Primary Prevention in Patients With Diabetes. Muluk et al. Diabetes Care 2023;46(12):2273–2277.

The Effectiveness of Shared Decision-making for Diabetes Prevention: 24- and 36-Month Results From the Prediabetes Informed Decision and Education (PRIDE) Trial. Duru et al. Diabetes Care 2023;46(12):2218–2222.

Trends in Preventive Care Services Among U.S. Adults With Diagnosed Diabetes, 2008–2020 Wittman et al. Diabetes Care 2023;46(12):2285–2291.

Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Wadden et al. Nat Med 2023;29(11):2909–2918.

Play Episode

Diabetes Core Update November 2023



Total Time: 31:20 | File Size: 43 MB


Association Between Changes in Carbohydrate Intake and Long Term Weight Changes: Prospective Cohort Study. Wan et al. BMJ. 2023;382:e073939.

Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5) : A Randomized Trial. Bajaj et al. Ann Intern Med. 2023;Epub ahead of print.

Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials. Rosenstock et al. Diabetes Care. 2023;46(11):1986–1992.

Tight Blood-Glucose Control without Early Parenteral Nutrition in the ICU. Gunst et al. N Engl J Med 2023;389(13):1180–1190.

Oral Semaglutide 50 mg Taken Once Per Day in Adults With Overweight or Obesity (OASIS 1): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. Knop et al. Lancet 2023;402(10403):705–719.

Play Episode

Diabetes Core Update October 2023



Total Time: 37:57 | File Size: 52 MB


Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. Kosiborod et al. N Engl J Med. 2023;389(12):1069–1084.

Real-world Accuracy of CGM in Inpatient Critical and Noncritical Care Settings at a Safety-Net Hospital. Finn et al. Diabetes Care 2023;46(10):1825–1830.

Leisure-Time Physical Activity and Risk of Microvascular Complications in Individuals With Type 2 Diabetes: A UK Biobank Study. Kristensen et al. Diabetes Care 2023;46(10):1816–1824.

Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function. Herold et al. Diabetes Care 2023;46(10):1848–1856.

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. Wharton et al. N Engl J Med. 2023;389(10):877–888.

Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes. Moura et al. Diabetes Care 2023;46(10):1807–1815.

Play Episode

Diabetes Core Update September 2023



Total Time: 38:41 | File Size: 53 MB


Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Frias et al. Lancet 2023;402(10403):720-730.

Association Between Diabetes Technology Use and Glycemic Outcomes in Adults With Type 1 Diabetes Over a Decade. Kalus et al. Diabetes Care 2023;46(9):1646–1651.

A Randomized Controlled Trial Comparing the Efficacy and Safety of IDegLira Versus Basal-Bolus in Patients With Poorly Controlled Type 2 Diabetes and Very High HbA1c ≥9–15%: DUAL HIGH Trial. Galindo et al. Diabetes Care 2023;46(9):1640–1645.

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Rosenstock et al. Lancet 2023;402(10401):529-544.

Play Episode


Total Time: 38:50 | File Size: 54 MB


Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin. Rosenstock et al. N Engl J Med 2023;Epub ahead of print.

Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. Jastreboff et al. N Engl J Med 2023;Epub ahead of print.

Effects of Tirzepatide Versus Insulin Glargine on Cystatin C–Based Kidney Function: A SURPASS-4 Post Hoc Analysis. Heerspink et al. Diabetes Care 2023;46(8):1501–1506.

Relationship Among Diabetes, Obesity, and Cardiovascular Disease Phenotypes: A UK Biobank Cohort Study. Brown et al. Diabetes Care 2023;46(8):1531–1540.

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Garvey et al. Lancet 2023;Epub ahead of print.

Play Episode


Total Time: 31:19 | File Size: 43 MB


Long-term effect of intensive lifestyle intervention on cardiometabolic risk factors and microvascular complications in patients with diabetes in real-world clinical practice: a 10-year longitudinal study. Tomah et al. BMJ Open Diabetes Res Care 2023;11(3):e003179.

Comparison of seven popular structured dietary programmes and risk of mortality and major cardiovascular events in patients at increased cardiovascular risk: systematic review and network meta-analysis. Karam et al. BMJ 2023; 380:e072003.

Beverage consumption and mortality among adults with type 2 diabetes: prospective cohort study. Ma et al. BMJ 2023;381:e073406.

Severe Mental Illness and Type 2 Diabetes Outcomes and Complications: A Nationwide Cohort Study. Fleetwood et al. Diabetes Care 2023;46(7):1363–1371.

High Prevalence of NASH and Advanced Fibrosis in Type 2 Diabetes: A Prospective Study of 330 Outpatients Undergoing Liver Biopsies for Elevated ALT, Using a Low Threshold. Castera et al. Diabetes Care 2023;46(7):1354–1362.

Is COVID-19 to Blame? Trends of Incidence and Sex Ratio in Youth-Onset Type 2 Diabetes in Germany. Denzer et al. Diabetes Care 2023;46(7):1379–1387.

Play Episode


Total Time: 30:42 | File Size: 43 MB


Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. Nissen et al. N Engl J Med 2023;388(15):1353-1364.

Cardiovascular and Renal Benefits of Novel Diabetes Drugs by Baseline Cardiovascular Risk: A Systematic Review, Meta-analysis, and Meta-regression. Rodriguez-Valadez et al. Diabetes Care 2023;46(6):1300–1310.

A National Physician Survey of Deintensifying Diabetes Medications for Older Adults With Type 2 Diabetes. Pilla et al. Diabetes Care 2023;46(6):1164–1168.

Higher Neighborhood Drivability Is Associated With a Higher Diabetes Risk in Younger Adults: A Population-Based Cohort Study in Toronto, Canada. den Braver et al. Diabetes Care 2023;46(6):1177–1184.

Quantifying the Relationship Between Physical Activity Energy Expenditure and Incident Type 2 Diabetes: A Prospective Cohort Study of Device-Measured Activity in 90,096 Adults. Strain et al. Diabetes Care 2023;46(6):1145–1155.

Glycemic Control Over Multiple Decades and Dementia Risk in People With Type 2 Diabetes. Moran et al. JAMA Neurol Published online April 17, 2023.

Play Episode


Total Time: 33:17 | File Size: 46 MB


Cardiovascular Safety in Type 2 Diabetes With Sulfonylureas as Second-line Drugs: A Nationwide Population-Based Comparative Safety Study. Wang et al. Diabetes Care 2023;46(5):967–977.

Noninvasive Hypoglycemia Detection in People With Diabetes Using Smartwatch Data. Lehmann et al. Diabetes Care 2023;46(5):993–997.

Trial of Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes. Wadwa et al. N Engl J Med. 2023;388(11):991–1001.

Safety and efficacy of an oral insulin (Capsulin) in patients with early-stage type 2 diabetes: A dose-ranging phase 2b study. New et al. Diabetes Obes Metab 2023;25(4):953–960.

Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial. Bue-Valleskey et al. Diabetes Care 2023;46(5):1060–1067.

Recommended and Prevalent Use of Glucagon-like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors in a National Population-Based Sample. Tang et al. Ann Intern Med 2023;176(4):582-583.

Play Episode


Total Time: 30:23 | File Size: 42 MB


Initiation of Continuous Glucose Monitoring Is Linked to Improved Glycemic Control and Fewer Clinical Events in Type 1 and Type 2 Diabetes in the Veterans Health Administration. Reaven et al. Diabetes Care 2023;46(4):854–863.

Trends in the Prevalence of Lean Diabetes Among U.S. Adults, 2015–2020. Adesoba and Brown. Diabetes Care 2023;46(4):885–889.

Vitamin D and Risk for Type 2 Diabetes in People With Prediabetes : A Systematic Review and Meta-analysis of Individual Participant Data From 3 Randomized Clinical Trials. Pittas et al. Ann Intern Med 2023;176(3):355-363.

Low-Carbohydrate Diet Scores and Mortality Among Adults With Incident Type 2 Diabetes. Hu et al. Diabetes Care 2023;46(4):874–884.

Trends in baseline HbA1c and body-mass index in randomised placebo-controlled trials of type 2 diabetes from 1987 to 2022: A systematic review and meta-analysis. Hu et al. EClinicalMedicine 2023;57:101868.

How sweet is your love? Disentangling the role of marital status and quality on average glycemic levels among adults 50 years and older in the English Longitudinal Study of Ageing. Ford and Robitaille et al. BMJ Open Diabetes Res Care 2023.

Play Episode


Total Time: 29:23 | File Size: 41 MB


Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study. Beernink et al. Diabetes Care 2023;46(3):602-607.

An Examination of Whether Diabetes Control and Treatments Are Associated With Change in Frailty Index Across 8 Years: An Ancillary Exploratory Study From the Action for Health in Diabetes (Look AHEAD) Trial. Simpson et al. Diabetes Care 2023;46(3):519-525.

Semaglutide Improves Cardiometabolic Risk Factors in Adults With Overweight or Obesity: STEP 1 and 4 Exploratory Analyses. Kosiborod et al. Diabetes Obes Metab 2023;25(2):468-478.

Glucagon Prescribing and Costs Among U.S. Adults With Diabetes, 2011–2021. Herges et al. Diabetes Care 2023;46(3):620-627.

Two-Year Follow-up From the T1GER Study: Continued Off-Therapy Metabolic Improvements in Children and Young Adults With New-Onset T1D Treated With Golimumab and Characterization of Responders. Rigby et al. Diabetes Care 2023;46(3):561–569.

Youth-Onset Type 2 Diabetes: The Epidemiology of an Awakening Epidemic. Perng et al. Diabetes Care 2023;46(3):490-499.

Play Episode


Total Time: 28:47 | File Size: 40 MB


Dietary Factors and All-Cause Mortality in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Prospective Observational Studies. Barbaresko et al. Diabetes Care 2023;46(2):469-477.

Prevalence and Predictors of Household Food Insecurity and Supplemental Nutrition Assistance Program Use in Youth and Young Adults With Diabetes: The SEARCH for Diabetes in Youth Study. Malik et al. Diabetes Care 2023;46(2):278-285.

Association of Sodium–Glucose Cotransporter 2 Inhibitors With Time to Dementia: A Population-Based Cohort Study. Wu et al. Diabetes Care 2023;46(2):297-304.

Concomitant Use of Sulfonylureas and β-Blockers and the Risk of Severe Hypoglycemia Among Patients With Type 2 Diabetes: A Population-Based Cohort Study. Dimakos et al. Diabetes Care 2023;46(2):377-383.

LY3437943, A Novel Triple GIP, GLP-1, and Glucagon Receptor Agonist in People With Type 2 Diabetes: A Phase 1b, Multicentre, Double-Blind, Placebo-Controlled, Randomised, Multiple-Ascending Dose Trial. Urva et al. Lancet 2022;400(10366):1869-1881.

Different Types of Industry-Produced and Ruminant Trans Fatty Acid Intake and Risk of Type 2 Diabetes: Findings From the NutriNet-Santé Prospective Cohort. Wendeu-Foyet et al. Diabetes Care 2023;46(2):321-330.

Play Episode


Total Time: 27:52 | File Size: 39 MB


Long-term Weight Training and Mortality in U.S. Male Health Professionals With and Without Type 2 Diabetes. Lee et al. Diabetes Care 2023;46(1):138–148.

Trajectories of Cognition and Daily Functioning Before and After Incident Diabetes. Ji et al. Diabetes Care 2023;46(1):75–82.

The Portfolio Diet and Incident Type 2 Diabetes: Findings From the Women's Health Initiative Prospective Cohort Study. Glenn et al. Diabetes Care 2023;46(1):28–37.

Racial Disparities in Access and Use of Diabetes Technology Among Adult Patients With Type 1 Diabetes in a U.S. Academic Medical Center. Kanbour et al. Diabetes Care 2023;46(1):56–64.

Deficits and Disparities in Early Uptake of Glucagon-Like Peptide 1 Receptor Agonists and SGLT2i Among Medicare-Insured Adults Following a New Diagnosis of Cardiovascular Disease or Heart Failure. Cromer et al. Diabetes Care 2023;46(1):65–74.

Sleep Duration and Risks of Incident Cardiovascular Disease and Mortality Among People With Type 2 Diabetes. Han et al. Diabetes Care 2023;46(1):101–110.

For previous episodes, please visit:
Subscribe on iTunes
Close Modal

or Create an Account

Close Modal
Close Modal